Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations: SABINA Findings From Europe and North America

Jennifer K Quint(Roland Hill (United Kingdom)), Yvette M. Weesie, Chantal Touboul(Inserm), Ralf J.P. van der Valk(AstraZeneca (United Kingdom)), Andrew Fong, Karissa Johnston, Christina Qian, Vicente Plaza(Hospital de Sant Pau), Njira Lugogo(University of Michigan), Joke C. Korevaar, Chantal Rahérison(Inserm), Ileen Gilbert(AstraZeneca (United States)), Keith Peres Da Costa, Sofie Arnetorp(AstraZeneca (Sweden)), Maciej Kupczyk(Karolinska Institutet), Brandie Walker(University of Calgary), Joseph Tkacz, Filip Surmont, Silvia Boarino, Janwillem Kocks(University Medical Center Groningen), Dorota Brzostek, Javier Nuevo(AstraZeneca (Spain)), C. Fabry-Vendrand, Stephen G. Noorduyn, Paul Hernandez(Dalhousie University), Ekaterina Maslova, Erika Penz(University of Saskatchewan), Liset van Dijk(University of Groningen), Michael Pollack, Helena Goike, Hitesh Gandhi, Marcia Vervloet(Netherlands Institute for Health Services Research), Wendy Beekman-Hendricks, Claudia Cabrera(AstraZeneca (Sweden))
The Journal of Allergy and Clinical Immunology In Practice
March 29, 2022
Cited by 79


Related Papers